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Introduction
Although a rare disease, multiple myeloma is one of the 
most common haematological malignancies accounting 
for more than 10% of all haematological cancers [1]. In 
Switzerland, each year around 570 individuals are diag-
nosed with multiple myeloma and 440 die of the disease 
[2]. During the last decades treatment improvements 
markedly increased survival of patients with multiple my-
eloma [3]. Successful treatment was begun in the 1960s 
using a combination of melphalan and prednisone achiev-
ing a median survival of 3-4 years [4, 5]. Until the 1990s, 
no treatment has shown further improvements in surviv-
al rates [5]. Thereafter, a new era of myeloma treatment 
was initiated with the introduction of high-dose chemo-
therapy combined with autologous stem cell transplanta-
tion [6-9] and new drugs, including thalidomide [10-12], 
bortezomib [13, 14] and lenalidomide [15-17]. Compared 
to former standard therapy, significant survival improve-
ments of these treatments are well documented in ran-
domized controlled trials. In addition, bisphosphonates 
[18-20] have shown anti-myeloma activity and a survival 
benefit in myeloma patients. 
Clinical trials are confined to selected patients. Therefore, 
their results are not readily transferable to the real-life 
setting. However, in recent years, several observational 
population-based studies have shown significant improve-
ments in survival for multiple myeloma patients in vari-
ous countries [3, 21-23]. However, regional differences in 
health care access, health care organization, and patient 
management may have a substantial impact on survival. 
Therefore, it is important to complement clinical trials 
and observational data from selected patient groups with 
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population-based epidemiological studies from different 
regions and countries.
We conducted an observational population-based study 
using cancer registry data from Switzerland to investigate 
survival trends in the era of high-dose chemotherapy with 
autologous stem cell transplantation and the first pro-
teasome inhibitors and immunomodulatory drugs before 
newer treatments antibody-therapies or second generation 
proteasome inhibitors became widely available.
Methods
Data sources and inclusion criteria
Incident multiple myeloma cases of the years 1991-2015 
and corresponding vital status information were obtained 
from the National Institute for Cancer Epidemiology and 
Registration (NICER) database. NICER is collecting and 
harmonizing cantonal cancer registry (CR) data and pro-
vides a central national database of cancer registration data 
in Switzerland. Due to the gradual introduction of cancer 
registration, national population coverage for this study 
varied from 53.5% (1991-1995) to 79.4% (2011-2015). 
Cantonal death rates by age, sex and calendar year were 
supplied by the Swiss Federal Statistical Office (SFSO), 
referring to all persons with permanent residence status 
in Switzerland. 
Analytic methods
Relative survival (RS) was estimated for consecutive 
5-year periods stratified by age at time of diagnosis (<65 
years, 65-74 years, 75+ years) using the Ederer II method 
[24]. We calculated RS up to 10-years after diagnosis us-
ing period analysis for the time period 2011-2015 and 
conventional cohort analysis for the prior periods [24]. 
Significance tests for RS were applied according to the 
method described by Parkin and Hakulinen [25].
Results
The demographic characteristics of observed multiple 
myeloma cases diagnosed in Switzerland between 1991 
and 2015 are presented in Table 1. The median age at 
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diagnosis remained stable throughout the observed time 
period with 70 years in males and 73 years in females. At 
time of diagnosis, around 30% each were diagnosed below 
the age of 65 years and between 65-74 years. The propor-
tion of patients aged 85 and older remained stable with 
around 9% across all time periods (data not shown). 
The survival curves showed an age-gradient with im-
proved RS in younger patients (Fig. 1). In patients diag-
nosed below age 65 years, 5-year RS improved from 46.4% 
(95%CI 40.5-52.0) in 1991-1995 to 71.4% (95% 67.0-
75.3; p<0.001) in 2011-2015 (Fig. 1-2). In patients diag-
nosed between age 65-74 years, 5-year RS increased from 
31.7 (95%CI 37.3-25.7) to 53.2% (95%CI 48.4-57.8; 
p<0.001) and from 21.9 (95%CI 16.8-27.6) to 29.4% 
(95%CI 25.3-33.7; <p<0.05) in patients 75+ years old. 
Ten years after diagnosis, only patients diagnosed before 
age 65 years and patients diagnosed between age 65-74 
years showed significant improvements in RS with 24.6% 
(95%CI 19.6-30.0) and 15.7 (95%CI 11.3-21.0) in 1991-
1995 and 45.0% (95%CI 39.7-50.3; p<0.01) and 26.9 
(95%CI 39.7-50.3) in 2011-2015 (p<0.05), respectively 
(Fig. 1).
Discussion
In Switzerland, relative survival of myeloma patients im-
proved between 1991 and 2015. This improvement, how-
ever, was strongest among patients less than 65 years old, 
which has also been observed in previous studies [22, 23, 26]. 
Autologous stem cell transplantation was mainly used for 
patients less than 65 years of age, especially in the ear-
lier time periods, and very rarely for patients older than 
Tab. 1. Patient characteristics of multiple myeloma cases 
reported to Swiss cancer registries, 1991-2015.
  N %
Overall
Sex
Males
Females
7,583
 
4,072
3,511
100.0%
 
53.7%
46.3%
Age
<65 years
65-74 years
>75 years
 
2,264
2,295
3,024
 
29.9%
30.3%
39.9%
Time period
1991-1995
1996-2000
2001-2005
2006-2010
2011-2015
 
1,074
1,257
1,329
1,713
2,210
 
14.2%
16.6%
17.5%
22.6%
29.1%
Population covered by cancer registration: 53.4% in 1991-1995, 57.8% in 1996-
2000, 58.1% in 2001-2005, 63.5% in 2006-2010 and 79.4% in 2011-2015. 
Fig. 1. Age-specific 
relative survival curves 
of multiple myeloma 
patients, 1991-1995 
and 2011-2015.
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75 years. Hence, the steep increase in survival benefit of 
the younger age group might be attributed to induction 
treatment, high-dose chemotherapy with autologous stem 
cell transplantation and the new drugs, while the flatter 
gains observed in the older as wells as in the mid age 
group might be more related to the new drugs. In Swit-
zerland, high-dose chemotherapy with autologous stem 
cell transplantation has increasingly been used since the 
1990s for younger patients [27-34], but less frequently for 
patients aged 65+ years old [31, 33, 34]. The introduc-
tion of therapies over the last two decades might explain 
the development of survival rates over time. Zolendronic 
acid was approved in 2001, bortezomib for second-line 
treatment in 2005 and lenalidomide for second-line 
treatment in 2007 [35]. Thalidomide has never been ap-
proved officially, but was available through a named pa-
tient program. Notably, lenalidomide was not approved 
or reimbursed for first-line treatment or in combination 
with bortezomib nor for maintenance treatment after au-
tologous transplantation during the whole period under 
observation, whereas off-label use in individual cases was 
possible. Newer agents were only approved in 2014 or 
later: pomalidomide (2014), carfilzomib (2015), panobi-
nostat (2015), elotuzumab (2016), daratumumab (2016) 
and ixazomib (2017) [35]. However, early access of these 
drugs, especially pomalidomide and carfilzomib, within 
clinical trials or on individual basis in named patient pro-
grams might have been possible. 
Implication on health care
Firstly, survival curves in our study did not reach a plateau, 
indicating the need for continuous surveillance and po-
tentially treatment even of long-term survivors. Secondly, 
even among younger patients, one out of four died from 
myeloma within 3 years after diagnosis. Hence, despite 
the introduction of new drugs with remarkable results in 
clinical trials in the relapsed setting and an improvement 
of survival rates, there is still a need for improvement in 
first-line treatment with long-lasting deep response and 
excellent tolerability in the real-life setting. Thirdly, giv-
en that improvements for the middle age group and the 
elderly still lag behind the younger patients there is an 
unmet need for effective treatment strategies in these age 
groups.
Strengths and limitations
Our study covers a period of 25 years. Although cancer 
registration in Switzerland is organized on a cantonal level 
and not all cancer registries have covered the entire study 
period, a recent evaluation demonstrated high complete-
ness across all registries and for most cancer types includ-
ing multiple myeloma [36]. 
Conclusion
There is a trend to improved relative survival in all age 
groups, which is most pronounced in patients younger 
than 75 years. The gradient of longer relative survival 
from younger to older myeloma patients that has intensi-
fied over time.
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